TScan Therapeutics (TCRX) Cash from Investing Activities Growth (1y) (2021 - 2026)
TScan Therapeutics (TCRX) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | -100.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100.52% |
| Dec 31, 2025 | -45.67% |
| Sep 30, 2025 | 139.56% |
| Jun 30, 2025 | 243.66% |
| Mar 31, 2025 | -62.59% |
| Dec 31, 2024 | 1,326.71% |
| Sep 30, 2024 | -34.09% |
| Jun 30, 2024 | -7,927.62% |
| Mar 31, 2024 | 4,415.39% |
| Dec 31, 2023 | 238.93% |
| Sep 30, 2023 | -14,384.43% |
| Jun 30, 2023 | 77.81% |
| Mar 31, 2023 | -57.82% |
| Dec 31, 2022 | 37.72% |
| Sep 30, 2022 | 50.29% |
| Jun 30, 2022 | 51.68% |
| Mar 31, 2022 | 82.05% |
| Dec 31, 2021 | -59.64% |
| Sep 30, 2021 | 36.49% |